| Name | Title | Contact Details |
|---|---|---|
Michael Ragan |
Director, Corporate and Securities Counsel | Profile |
Thomas Beetham |
Chief Legal Officer | Profile |
William Neeley |
Senior Director, Head of Intellectual Property | Profile |
Zoran Zdraveski |
Senior Vice President, Chief Legal Officer and Corporate Secretary | Profile |
Zoran Zdraveski |
Senior Vice President, Chief Legal Officer and Corporate Secretary | Profile |
William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
CoMentis is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RareCyte is a company focused on characterizing and isolating rare cells from blood.
Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.
Immunocore is a privately owned British clinical-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.